Correlation between immuno-related adverse events (IRAEs) occurrence and clinical outcome in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: IRAENE trial, an Italian multi-institutional retrospective study

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Background: Immunotherapy (IO) has brought dramatic clinical benefits to patients with mRCC. Most patients tolerate IO, but serious irAE have been reported. Some studies indicate the correlation of irAEs and clinical response in other cancer types such as lung cancer and melanoma. For mRCC, the impact of irAE on clinical outcome is unknown.